213 related articles for article (PubMed ID: 8251109)
1. The domestic drug regulatory process: why time is of the essence.
Katz R
Epilepsy Res Suppl; 1993; 10():91-106. PubMed ID: 8251109
[No Abstract] [Full Text] [Related]
2. Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods.
Browne TR
Epilepsy Res Suppl; 1993; 10():31-44. PubMed ID: 8251105
[No Abstract] [Full Text] [Related]
3. Study population selection.
Treiman DM
Epilepsy Res Suppl; 1993; 10():125-35. PubMed ID: 8251088
[No Abstract] [Full Text] [Related]
4. Sources of variability in clinical trials of new drugs for epilepsy.
Leppik IE
Epilepsy Res Suppl; 1993; 10():157-66. PubMed ID: 8251091
[No Abstract] [Full Text] [Related]
5. External influences on protocol design.
Spilker B
Epilepsy Res Suppl; 1993; 10():115-24. PubMed ID: 8251087
[No Abstract] [Full Text] [Related]
6. Protocol design.
Wilensky AJ
Epilepsy Res Suppl; 1993; 10():107-13. PubMed ID: 8251086
[No Abstract] [Full Text] [Related]
7. European investigational antiepilepsy drug trials.
Sussman NM
Epilepsy Res Suppl; 1993; 10():149-55. PubMed ID: 8251090
[No Abstract] [Full Text] [Related]
8. Preparing for an FDA audit.
Barnes D
Epilepsy Res Suppl; 1993; 10():245-50. PubMed ID: 8251103
[No Abstract] [Full Text] [Related]
9. Ethical considerations.
Treiman DM
Epilepsy Res Suppl; 1993; 10():137-48. PubMed ID: 8251089
[No Abstract] [Full Text] [Related]
10. The role of the pharmacist in investigational AED trials.
Graves NM
Epilepsy Res Suppl; 1993; 10():201-9. PubMed ID: 8251098
[No Abstract] [Full Text] [Related]
11. Patient recruitment and compliance issues in clinical trials.
Cramer JA
Epilepsy Res Suppl; 1993; 10():211-22. PubMed ID: 8251099
[No Abstract] [Full Text] [Related]
12. Obstacles encountered in designing antiepileptic drug trials.
French JA
Epilepsy Res Suppl; 1993; 10():81-9. PubMed ID: 8251107
[No Abstract] [Full Text] [Related]
13. Role of the Institutional Review Board in clinical trials.
Skolnick BE
Epilepsy Res Suppl; 1993; 10():193-200. PubMed ID: 8251097
[No Abstract] [Full Text] [Related]
14. Accelerated approval and oncology drug development timelines.
Lanthier ML; Sridhara R; Johnson JR; Farrell A; Keegan P; Justice R; Pazdur R
J Clin Oncol; 2010 May; 28(14):e226-7; author reply e228. PubMed ID: 20194846
[No Abstract] [Full Text] [Related]
15. Science and regulatory rituals associated with the drug development process.
Versteegh LR
Food Drug Law J; 1997; 52(2):155-61. PubMed ID: 10557552
[No Abstract] [Full Text] [Related]
16. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
17. Progress and deficiencies in the registration of clinical trials.
Wood AJ
N Engl J Med; 2009 Feb; 360(8):824-30. PubMed ID: 19228628
[No Abstract] [Full Text] [Related]
18. Moment of reckoning.
Wadman M
Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
[No Abstract] [Full Text] [Related]
19. Trouble at the office.
Allison M
Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
[No Abstract] [Full Text] [Related]
20. Clinical development of drugs for epilepsy: a review of approaches in the United States and Europe.
Porter RJ; Baulac M; Nohria V
Epilepsy Res; 2010 May; 89(2-3):163-75. PubMed ID: 20347575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
